Pharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 1, 2005
June 15, 2019
097d6c1f-5f70-4be5-acc2-a2029bde4dab
Related Documents
Establishment and Operation of Clinical Trial Data Monitoring Committees: Guidance for Clinical Trial Sponsors
Guidance DocumentMarch 28, 2006Center for Biologics Evaluation and Research
Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C: Guidance for Industry and FDA Staff
Guidance DocumentMarch 4, 2022Office of Inspections and Investigations
Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices: Guidance for Industry and Food and Drug Administration Staff
Guidance DocumentJune 21, 2016Center for Devices and Radiological Health
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.